Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Pfizer Receives Expanded FDA Approval for IBRANCE (Palbociclib) in HR+, HER2– Metastatic Breast Cancer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HR2–) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy. [Pfizer Inc.] Press Release